跳至主要内容

New Animal Model Developed to Aid Zika Studies

 When battling emerging infectious diseases, finding a model that accurately recapitulates the pathogenesis of the infection is critical to developing effective therapeutic interventions. Yet, as most scientists can attest, the things that are the most critical are also most often the most difficult to obtain. An alternative animal model that mimics key features of the Zika virus infection, including its lingering presence in bodily fluids, has been developed at Texas Biomedical Research Institute in San Antonio.

Findings from the new study were published recently in Scientific Reports, in an article entitled “Experimental Zika Virus Inoculation in a New World Monkey Model Reproduces Key Features of the Human Infection.”

The research team found that acute infections in male marmosets, a New World monkey, resemble the human illness the Zika virus creates in people, including the presence of the virus in semen, saliva, and urine up to two weeks after the initial infection. The primary mode of transmission for the Zika virus is through mosquito bites. Moreover, according to the Centers for Disease Control and Prevention, the disease can be spread through sexual contact.

"Given the key similarities to human infections, a marmoset model of Zika may be useful for testing of new drug and vaccines," noted senior study investigator Jean Patterson, Ph.D., a Texas Biomedical Research Institute virologist. "Having an animal model of Zika infection to study may help us identify places where we might be able to block transmission." Like 80% of humans infected with the Zika virus, most of the nonhuman primates used in the current study lacked any apparent clinical symptoms. 

Zika Studies Animal Model Develop

Zika was first identified in Africa in the mid-20th century. It emerged as an infectious threat in the Western Hemisphere in 2015 in Brazil, where it made news for creating a spate of congenital disabilities, including the devastating brain anomaly microcephaly. A year ago, Texas saw its first documented cases of the Zika virus transmitted by local mosquitoes. The handful of cases along the Texas–Mexico border likely won't be the state's last encounter with this emerging virus, according to public health reports.

The Texas researchers looked at Zika infection in the common marmoset (Callithrix jacchus) and determined it to be a good model for studying the pathogenesis of the disease. Additionally, since the primates are small (about the size of a rat), they hold advantages over other animal models.

"That size can be an advantage when testing experimental vaccines and therapeutics that are available in limited quantities," noted co-senior study investigator Suzette Tardif, Ph.D., associate director of research at the Southwest National Primate Research Center at Texas Biomed.

These monkeys have been shown to have a high susceptibility to infection by a variety of pathogens, including Ebola and Lassa viruses that affect humans, making marmosets useful for drug and vaccine testing. Recently, Zika virus was discovered in serum and saliva from marmosets living in the wild in Brazil, suggesting that these nonhuman primates are "a potential reservoir for maintaining Zika virus in endemic countries," according to Dr. Patterson's report.

The research team was optimistic about their findings and is planning the next steps in testing various vaccines. Scientists around the world are working to discover more about how the disease is transmitted from pregnant mother to the fetus, including scientists at Texas Biomed, and this new model could prove to be invaluable in these studies.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati